MONAHAN JOHN J 4

4 · Anixa Biosciences Inc · Filed Sep 20, 2019

Form 4

Period: 2019-09-20

Director

Transactions

Award
Employee Stock Option
2019-09-20+6,000→ 6,000 total
Exercise: $3.13Exp: 2026-08-23→ Common Stock (6,000 underlying)
Disposition to Issuer
Employee Stock Option
2019-09-20−6,000→ 0 total
Exercise: $0.67Exp: 2026-08-23→ Common Stock (6,000 underlying)
Disposition to Issuer
Employee Stock Option
2019-09-20−12,000→ 0 total
Exercise: $0.67Exp: 2027-01-03→ Common Stock (12,000 underlying)
Award
Employee Stock Option
2019-09-20+12,000→ 12,000 total
Exercise: $5.30Exp: 2027-01-03→ Common Stock (12,000 underlying)

Footnotes (3)

[F1]These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options.
[F2]The option was originally granted on August 23, 2016 and vested 50% on September 30, 2016 and 50% on December 31, 2016.
[F3]The option was originally granted on January 3, 2017 and vests and become exercisable in four (4) equal installments on each March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017.

Documents

1 file